The measles vaccine is one of the most effective vaccines ever developed. A single dose prevents measles in about 93% of recipients, and the standard two-dose series raises that figure to roughly 97%. That level of protection has translated into enormous real-world impact: measles vaccination prevented an estimated 59 million deaths worldwide between 2000 and 2024.
Protection After One Dose vs. Two
After a single dose, about 93 out of every 100 children develop strong immunity to measles. The small percentage who don’t respond to the first shot are experiencing what’s called primary vaccine failure, meaning their immune system simply didn’t mount a sufficient response that time around. This happens in roughly 2% to 10% of people who receive one dose.
The second dose exists to catch those non-responders. When children receive both shots (the first typically at 12 to 15 months, the second at 4 to 6 years), the overall effectiveness climbs to about 97%. That second dose isn’t a booster in the traditional sense. It’s a second opportunity for the immune system to learn the virus, and it works: nearly all children who missed protection the first time around gain it with dose two.
How the Vaccine Creates Lasting Immunity
The measles vaccine contains a live but weakened version of the virus. When it enters your body, it’s strong enough to trigger a full immune response but too weak to cause actual disease. Your immune system treats it like a real infection, producing antibodies to neutralize the virus and building a library of specialized memory cells designed to recognize measles if you ever encounter it again.
This process generates both arms of the immune response. One branch creates antibodies that can immediately intercept the virus. The other builds long-lived memory cells that can rapidly multiply and launch a targeted attack years or even decades later. It’s this dual response that makes measles vaccination so durable compared to vaccines for some other diseases.
How Long Protection Lasts
For most people, two doses of the measles vaccine provide protection that lasts a lifetime. A 2024 mathematical modeling study published in The Lancet Public Health found that vaccine-induced immunity does wane, but extremely slowly, at a rate of about 0.04% per year. That means a vaccinated person in their 30s still has overwhelming protection against measles.
That said, the waning is not zero. Immunological studies from Canada, Japan, and the Czech Republic have detected lower antibody levels in young adults who received their two doses more than 20 years earlier. By comparison, people who survived a natural measles infection showed no similar decline. The practical consequence is that breakthrough infections become slightly more common in vaccinated adults over time, though these cases tend to be milder. For the vast majority of vaccinated people, meaningful protection persists for decades without any additional doses.
What Happens If a Vaccinated Person Gets Measles
Breakthrough cases do occur, but they typically look very different from measles in an unvaccinated person. A study comparing vaccinated and unvaccinated children who contracted measles found a stark difference in severity. Among unvaccinated children, 44% experienced very serious infection. Among vaccinated children, that figure dropped to about 19%. Vaccinated children were far more likely to have mild illness, while unvaccinated children were far more likely to develop dangerous complications.
This matters because measles is not a mild childhood illness. It kills roughly 95,000 people a year globally, mostly young children. Even when vaccination doesn’t completely prevent infection, it dramatically reduces the risk of the severe outcomes that make measles deadly: pneumonia, brain swelling, and immune system damage.
Why Community Vaccination Rates Matter
Measles is extraordinarily contagious. One infected person can spread it to 12 to 18 others in an unvaccinated population, making it one of the most transmissible diseases known. Because of this, communities need very high vaccination rates to prevent outbreaks. The commonly cited threshold is around 92% to 95% of the population vaccinated with two doses.
Data from the 2025 U.S. measles outbreaks illustrate this vividly. States in the lowest quartile for kindergarten MMR coverage (at or below 92%) accounted for 87% of all U.S. cases. No state with coverage at 96% or above reported more than five cases. Modeling work suggests that every single percentage point drop in two-dose coverage increases outbreak probability by roughly 14%. Some of the hardest-hit Texas counties had kindergarten coverage as low as 70.5%, well below the national average of 92.7%.
The federal Healthy People 2030 benchmark targets 95% coverage in every state. When communities fall below that level, the people most at risk are those who can’t be vaccinated: infants too young for their first dose, people with compromised immune systems, and the small percentage of vaccinated individuals whose immunity didn’t fully take hold.
The Global Picture
Before widespread vaccination, measles killed an estimated 780,000 people per year as of 2000. By 2024, that number had fallen to about 95,000, a reduction of nearly 88%. The World Health Organization estimates that accelerated immunization efforts prevented approximately 59 million deaths over that 24-year span. Few medical interventions in human history have saved lives on that scale.
Despite this progress, measles remains a leading cause of vaccine-preventable death in children worldwide. The gaps in protection are almost entirely gaps in access and uptake, not gaps in the vaccine’s effectiveness. Where two-dose coverage reaches 95% or higher, measles transmission essentially stops. Where it doesn’t, outbreaks continue to claim lives.